RSS   Newsletter   Contact   Advertise with us

Lilly begins phase 3 clinical trial with baricitinib for hospitalized coronavirus patients

Christian Fernsby ▼ | June 19, 2020
Eli Lilly and Company announced that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo‑controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, in hospitalized adults with coronavirus.
Eli Lilly
Trial   Eli Lilly
Baricitinib, marketed as OLUMIANT, is approved in 70 countries as a treatment for adults with moderately to severely active rheumatoid arthritis (RA).

Topics: Lilly

Lilly expects to enroll 400 patients in the trial, with data expected in the next few months.

The study will be conducted in the U.S., Europe and Latin America and includes patients hospitalized with SARS-CoV-2 infection who have at least one elevated marker of inflammation but do not require invasive mechanical ventilation at study entry.